At Delee, we aim to radically change the way cancer is detected, monitored and treated. Through the development of the CytoCatchâ˘, which is a highly sensitive automated benchtop device, we have made possible to rapidly isolate and efficiently analyze circulating tumor cells from blood samples. This innovative technology enables not only the early detection of cancer, but also the continuous monitoring of the diseaseâs evolution and the effectiveness of therapies that are being administered; increasing the patientâs chances of defeating cancer.
No articles found.
 
                  The Healthereum Patient Behavior Management platform is a full cycle communication...
The Healthereum Patient Behavior Management pla...
 
                  Helen of Troy Limited (NASDAQ: HELE) is a leading global consumer products company...
Helen of Troy Limited (NASDAQ: HELE) is a leadi...
 
                  HTG Molecular Diagnostics, Inc. ("HTG") is a provider of instruments, reagents, an...
HTG Molecular Diagnostics, Inc. ("HTG") is a pr...
 
                  Cloud DX creates easy-to-use medical devices and mobile apps that help people get ...
Cloud DX creates easy-to-use medical devices an...
 
                  ALR Technologies is a medical device company providing remote monitoring and care ...
ALR Technologies is a medical device company pr...
 
                  Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
 
                  PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
Join the National Investor Network and get the latest information with your interests in mind.